November 1, 2016 04:00 PM EDT

Fast biotech: Gilead hands $200M to computational wiz Nimbus as it speeds into PhII NASH trial

John Carroll

Editor & Founder

When Nimbus Therapeutics CEO Don Nicholson structured his $1.2 billion licensing deal with Gilead $GILD earlier this year, he built it with the Big Biotech …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Fast biotech: Gilead hands $200M to computational wiz Nimbus as it speeds into PhII NASH trial

John Carroll

Editor & Founder

Sign up to read this article for free.

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

US drugs rely heavily on ingredients made overseas, new report shows

Biotech seed rounds sink to lowest level in years as industry slump drags on

Pharma's wins and losses in Trump's sprawling executive order on drug prices

Eli Lilly reports first Phase 3 data for oral GLP-1, posting a win in diabetes

Exclusive: VelaVigo inks another US biotech deal as China drug development scene booms

New York-based partnership sets the standard for expanding clinical trial access for underserved and diverse ...

Fast biotech: Gilead hands $200M to com­pu­ta­tion­al wiz Nim­bus as it speeds in­to PhII NASH tri­al

Editor & Founder

Sign up to read this article for free.

Celldex Therapeutics

Hampton, NJ, USA

Fast biotech: Gilead hands $200M to computational wiz Nimbus as it speeds into PhII NASH trial